It is also interesting to note that the only OMP whose approval was based on five main clinical trials (fosdenopterin) is intended to treat an ultra-rare disease, molybdenum-cofactor-deficiency (MoCD) and was approved under exceptional circumstances. Here, OMP is linked to sulfite oxidase deficiency due to molybdenum cofactor deficiency.